Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 352

1.

Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.

Uhland K, Siphos B, Arkona C, Schuster M, Petri B, Steinmetzer P, Mueller F, Schweinitz A, Steinmetzer T, Van De Locht A.

Int J Oncol. 2009 Aug;35(2):347-57.

PMID:
19578749
2.

In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.

Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K.

Int J Oncol. 2005 Oct;27(4):1061-70.

PMID:
16142324
3.

The hepatocyte growth factor regulatory factors in human breast cancer.

Parr C, Watkins G, Mansel RE, Jiang WG.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11.

4.

A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.

Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H.

Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):217-27.

5.

Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.

Xue A, Xue M, Jackson C, Smith RC.

Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1731-8. doi: 10.1016/j.biocel.2009.03.004.

PMID:
19433314
6.

Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.

Wang W, Gao J, Man XH, Li ZS, Gong YF.

Oncol Rep. 2009 Jun;21(6):1439-47.

PMID:
19424621
8.

The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.

Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E.

Cancer Res. 2006 Apr 15;66(8):4149-58.

9.

Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.

Tsai WC, Sheu LF, Chao YC, Chen A, Chiang H, Jin JS.

Chin J Physiol. 2007 Oct 31;50(5):225-31.

PMID:
18274158
10.

Human pancreatic ribonuclease 1: expression and distribution in pancreatic adenocarcinoma.

Peracaula R, Cleary KR, Lorenzo J, de Llorens R, Frazier ML.

Cancer. 2000 Sep 15;89(6):1252-8.

PMID:
11002220
11.

Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression.

Zhou L, Zhang R, Yao W, Wang J, Qian A, Qiao M, Zhang Y, Yuan Y.

Tohoku J Exp Med. 2009 Feb;217(2):123-31.

12.

Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.

Owen KA, Qiu D, Alves J, Schumacher AM, Kilpatrick LM, Li J, Harris JL, Ellis V.

Biochem J. 2010 Feb 9;426(2):219-28. doi: 10.1042/BJ20091448.

PMID:
20015050
13.

Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.

Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC.

Clin Cancer Res. 2002 Apr;8(4):1101-7.

14.

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L.

Mod Pathol. 2007 May;20(5):570-8.

15.

Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma.

Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP.

Clin Cancer Res. 2004 Nov 1;10(21):7427-37.

16.

Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway.

Ketterer K, Kong B, Frank D, Giese NA, Bauer A, Hoheisel J, Korc M, Kleeff J, Michalski CW, Friess H.

Cancer Lett. 2009 May 8;277(1):72-81. doi: 10.1016/j.canlet.2008.11.028.

PMID:
19118941
17.

Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.

Gao DJ, Xu M, Zhang YQ, Du YQ, Gao J, Gong YF, Man XH, Wu HY, Jin J, Xu GM, Li ZS.

Pancreas. 2010 Oct;39(7):994-1001. doi: 10.1097/MPA.0b013e3181db0086.

PMID:
20467347
18.

Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions.

Hermanova M, Trna J, Nenutil R, Dite P, Kala Z.

Eur J Gastroenterol Hepatol. 2008 Aug;20(8):732-9. doi: 10.1097/MEG.0b013e3282f945fb.

PMID:
18617777
19.

Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma.

Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ.

J Am Coll Surg. 2007 May;204(5):996-1005; discussion 1005-6.

PMID:
17481528
20.

Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.

Parr C, Sanders AJ, Davies G, Martin T, Lane J, Mason MD, Mansel RE, Jiang WG.

Clin Cancer Res. 2007 Jun 15;13(12):3568-76.

Items per page

Supplemental Content

Support Center